(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of 75.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.15%.
Cormedix's revenue in 2025 is $82,553,827.On average, 9 Wall Street analysts forecast CRMD's revenue for 2025 to be $19,072,972,357, with the lowest CRMD revenue forecast at $16,564,138,221, and the highest CRMD revenue forecast at $24,485,380,146. On average, 9 Wall Street analysts forecast CRMD's revenue for 2026 to be $28,891,948,241, with the lowest CRMD revenue forecast at $21,695,073,674, and the highest CRMD revenue forecast at $36,464,571,418.
In 2027, CRMD is forecast to generate $28,417,175,628 in revenue, with the lowest revenue forecast at $19,494,841,736 and the highest revenue forecast at $33,375,836,447.